Yayın:
Apoptosis-Inducing Activity and Antiproliferative Effect of Gossypin on PC-3 Prostate Cancer Cells

dc.contributor.authorCinar, Irfan
dc.date.accessioned2026-01-04T15:08:40Z
dc.date.issued2021-03-01
dc.description.abstractAim: The rapid growth, morbidity and mortality of prostate cancer, and the lack of effective treatment have attracted great interest of researchers to find novel cancer therapies aiming at the effect of gossypin on cell proliferation and apoptosis of PC-3 cells. Methods: The effect of gossypin on cell viability was determined using MTT assay at 5-100μg/ml and cisplatin (50μM) in a time-dependent manner in PC-3 cell lines. The expression levels of caspase-3 (CASP3) and caspase-9 (CASP9) for apoptosis and Nuclear Factor Kappa B (NFKB1) for survival, inflammation, and growth were evaluated by real-time PCR. Hoechst staining was used to analyze apoptosis. Results: Gossypin showed an anti-proliferative effect on PC3 cell line in a time- and dose-dependent manner. In addition, gossypin led to a significant increase in apoptosis genes (CASP3, CASP9) when compared to control while it caused a decrease in the level of NFKB1, which is accepted as apoptosis inhibitor (p<0.05) (cisplatin-like). Gossypin 50 and 100μM significantly induced apoptotic mechanism in PC-3 cells. However, no apoptotic or commonly stained nuclei have been observed in control group cells. Conclusion: The results indicated that gossypin can be defined as a promising anticancer agent for PC-3 human prostate cancer cell line.
dc.description.urihttps://doi.org/10.2174/1871520620666200721103422
dc.description.urihttps://pubmed.ncbi.nlm.nih.gov/32698736
dc.description.urihttps://dx.doi.org/10.2174/1871520620666200721103422
dc.identifier.doi10.2174/1871520620666200721103422
dc.identifier.endpage450
dc.identifier.issn1871-5206
dc.identifier.openairedoi_dedup___::5ca5465ee3a89aa799d593a55b5d617f
dc.identifier.orcid0000-0002-9826-2556
dc.identifier.pubmed32698736
dc.identifier.scopus2-s2.0-85099974940
dc.identifier.startpage445
dc.identifier.urihttps://hdl.handle.net/20.500.12597/38627
dc.identifier.volume21
dc.identifier.wos000631813100003
dc.language.isoeng
dc.publisherBentham Science Publishers Ltd.
dc.relation.ispartofAnti-Cancer Agents in Medicinal Chemistry
dc.subjectFlavonoids
dc.subjectDose-Response Relationship, Drug
dc.subjectMolecular Structure
dc.subjectCell Survival
dc.subjectAntineoplastic Agents
dc.subjectApoptosis
dc.subjectStructure-Activity Relationship
dc.subjectPC-3 Cells
dc.subjectHumans
dc.subjectDrug Screening Assays, Antitumor
dc.subjectCell Proliferation
dc.subject.sdg3. Good health
dc.titleApoptosis-Inducing Activity and Antiproliferative Effect of Gossypin on PC-3 Prostate Cancer Cells
dc.typeArticle
dspace.entity.typePublication
local.api.response{"authors":[{"fullName":"Irfan Cinar","name":"Irfan","surname":"Cinar","rank":1,"pid":{"id":{"scheme":"orcid","value":"0000-0002-9826-2556"},"provenance":null}}],"openAccessColor":null,"publiclyFunded":false,"type":"publication","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"keyword","value":"Flavonoids"},"provenance":null},{"subject":{"scheme":"FOS","value":"0301 basic medicine"},"provenance":null},{"subject":{"scheme":"FOS","value":"0303 health sciences"},"provenance":null},{"subject":{"scheme":"keyword","value":"Dose-Response Relationship, Drug"},"provenance":null},{"subject":{"scheme":"keyword","value":"Molecular Structure"},"provenance":null},{"subject":{"scheme":"keyword","value":"Cell Survival"},"provenance":null},{"subject":{"scheme":"keyword","value":"Antineoplastic Agents"},"provenance":null},{"subject":{"scheme":"keyword","value":"Apoptosis"},"provenance":null},{"subject":{"scheme":"SDG","value":"3. Good health"},"provenance":null},{"subject":{"scheme":"keyword","value":"Structure-Activity Relationship"},"provenance":null},{"subject":{"scheme":"FOS","value":"03 medical and health sciences"},"provenance":null},{"subject":{"scheme":"keyword","value":"PC-3 Cells"},"provenance":null},{"subject":{"scheme":"keyword","value":"Humans"},"provenance":null},{"subject":{"scheme":"keyword","value":"Drug Screening Assays, Antitumor"},"provenance":null},{"subject":{"scheme":"keyword","value":"Cell Proliferation"},"provenance":null}],"mainTitle":"Apoptosis-Inducing Activity and Antiproliferative Effect of Gossypin on PC-3 Prostate Cancer Cells","subTitle":null,"descriptions":["<jats:sec> <jats:title>Aim:</jats:title> <jats:p>The rapid growth, morbidity and mortality of prostate cancer, and the lack of effective treatment have attracted great interest of researchers to find novel cancer therapies aiming at the effect of gossypin on cell proliferation and apoptosis of PC-3 cells.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>The effect of gossypin on cell viability was determined using MTT assay at 5-100μg/ml and cisplatin (50μM) in a time-dependent manner in PC-3 cell lines. The expression levels of caspase-3 (CASP3) and caspase-9 (CASP9) for apoptosis and Nuclear Factor Kappa B (NFKB1) for survival, inflammation, and growth were evaluated by real-time PCR. Hoechst staining was used to analyze apoptosis.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p>Gossypin showed an anti-proliferative effect on PC3 cell line in a time- and dose-dependent manner. In addition, gossypin led to a significant increase in apoptosis genes (CASP3, CASP9) when compared to control while it caused a decrease in the level of NFKB1, which is accepted as apoptosis inhibitor (p&lt;0.05) (cisplatin-like). Gossypin 50 and 100μM significantly induced apoptotic mechanism in PC-3 cells. However, no apoptotic or commonly stained nuclei have been observed in control group cells.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion:</jats:title> <jats:p>The results indicated that gossypin can be defined as a promising anticancer agent for PC-3 human prostate cancer cell line.</jats:p> </jats:sec>"],"publicationDate":"2021-03-01","publisher":"Bentham Science Publishers Ltd.","embargoEndDate":null,"sources":["Crossref"],"formats":null,"contributors":null,"coverages":null,"bestAccessRight":null,"container":{"name":"Anti-Cancer Agents in Medicinal Chemistry","issnPrinted":"1871-5206","issnOnline":null,"issnLinking":null,"ep":"450","iss":null,"sp":"445","vol":"21","edition":null,"conferencePlace":null,"conferenceDate":null},"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"doi_dedup___::5ca5465ee3a89aa799d593a55b5d617f","originalIds":["LiveAll1","10.2174/1871520620666200721103422","50|doiboost____|5ca5465ee3a89aa799d593a55b5d617f","32698736","3045103819"],"pids":[{"scheme":"doi","value":"10.2174/1871520620666200721103422"},{"scheme":"pmid","value":"32698736"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":20,"influence":3.124467e-9,"popularity":1.7340753e-8,"impulse":15,"citationClass":"C4","influenceClass":"C5","impulseClass":"C4","popularityClass":"C4"}},"instances":[{"pids":[{"scheme":"doi","value":"10.2174/1871520620666200721103422"}],"type":"Article","urls":["https://doi.org/10.2174/1871520620666200721103422"],"publicationDate":"2021-03-01","refereed":"peerReviewed"},{"pids":[{"scheme":"pmid","value":"32698736"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.2174/1871520620666200721103422"}],"type":"Article","urls":["https://pubmed.ncbi.nlm.nih.gov/32698736"],"publicationDate":"2021-10-19","refereed":"nonPeerReviewed"},{"alternateIdentifiers":[{"scheme":"doi","value":"10.2174/1871520620666200721103422"},{"scheme":"mag_id","value":"3045103819"}],"type":"Article","urls":["https://dx.doi.org/10.2174/1871520620666200721103422"],"refereed":"nonPeerReviewed"}],"isGreen":false,"isInDiamondJournal":false}
local.import.sourceOpenAire
local.indexed.atWOS
local.indexed.atScopus
local.indexed.atPubMed

Dosyalar

Koleksiyonlar